Kim A. Connelly


Scientist, Keenan Research Centre for Biomedical Science


Dr. Kim Connelly is a Cardiologist and Scientist who is both nationally recognized as an expert in human and rodent echocardiography, cardiovascular MRI and the impact of diabetes upon cardiac function. His work has been recognized evident by winning the “Young Investigator of the Year Award” in 2012 by the Canadian Cardiovascular Society an Early Researcher Award in 2014, and a Canadian Institutes of Health Research (CIHR) New Investigator award in 2014.

Dr. Connelly runs a basic research laboratory at the Keenan Research Centre for Biomedical Science (KRCBS) at St. Michael’s Hospital where he focuses upon basic mechanisms of disease – primarily around the role of pathological extracellular matrix accumulation and the pro-sclerotic cytokine transforming growth factor beta, with a focus upon translating discoveries into therapies in humans. He is the Director of the Krembil Stem Cell Facility at St. Michael’s Hospital and uses stem cell based therapies to improve cardiac and renal dysfunction as a result of diabetes. He collaborates extensively not only locally in Toronto but also nationally and internationally – with research support from the Heart and Stroke Foundation (HSF) of Canada, CIHR and Canadian Foundation for Innovation along with significant research support from the pharmaceutical industry.

Locally, he sits on the executive of the University of Toronto Cardiovascular research network, and has been a reviewer for both the CIHR “CSB” panel, along with the Heart and Stroke Foundation of Canada (HSF). He was the national spokesperson for the HSF of Canada “heart healthy month” in February 2015.

Recent Publications

  1. Chow, BJW, Coyle, D, Hossain, A, Laine, M, Hanninen, H, Ukkonen, H et al.. Computed tomography coronary angiography for patients with heart failure (CTA-HF): a randomized controlled trial (IMAGE-HF 1C). Eur Heart J Cardiovasc Imaging. 2020; :. doi: 10.1093/ehjci/jeaa109. PubMed PMID:32588042 .
  2. Kenk, M, Grégoire, JC, Coté, MA, Connelly, KA, Davis, MK, Dresser, G et al.. Optimizing screening and management of cardiovascular health in prostate cancer. Can Urol Assoc J. 2020; :. doi: 10.5489/cuaj.6685. PubMed PMID:32569573 .
  3. Banks, L, Altaha, MA, Yan, AT, Dorian, P, Konieczny, K, Deva, DP et al.. Left Ventricular Fibrosis in Middle-Age Athletes and Physically Active Adults. Med Sci Sports Exerc. 2020; :. doi: 10.1249/MSS.0000000000002411. PubMed PMID:32472930 .
  4. Karam, N, Mehr, M, Taramasso, M, Besler, C, Ruf, T, Connelly, KA et al.. Value of Echocardiographic Right Ventricular and Pulmonary Pressure Assessment in Predicting Transcatheter Tricuspid Repair Outcome. JACC Cardiovasc Interv. 2020;13 (10):1251-1261. doi: 10.1016/j.jcin.2020.02.028. PubMed PMID:32360260 .
  5. Ghosh-Swaby, OR, Goodman, SG, Leiter, LA, Cheng, A, Connelly, KA, Fitchett, D et al.. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2020;8 (5):418-435. doi: 10.1016/S2213-8587(20)30038-3. PubMed PMID:32333878 .
  6. Dorian, P, Goodman, JM, Connelly, KA. Policies to Prevent Sudden Cardiac Death in Young Athletes: Challenging, But More Testing Is Not the Answer. J Am Heart Assoc. 2020;9 (8):e016332. doi: 10.1161/JAHA.120.016332. PubMed PMID:32306795 .
  7. Dorian, P, Yan, AT, Connelly, KA. Predicting Sudden Death in Dilated Cardiomyopathy: The Potential Power of Magnetic Resonance Imaging as a Critical Tool. Can J Cardiol. 2019; :. doi: 10.1016/j.cjca.2019.12.027. PubMed PMID:32249064 .
  8. Orban, M, Rommel, KP, Ho, EC, Unterhuber, M, Pozzoli, A, Connelly, KA et al.. Transcatheter Edge-to-Edge Tricuspid Repair for Severe Tricuspid Regurgitation Reduces Hospitalizations for Heart Failure. JACC Heart Fail. 2020;8 (4):265-276. doi: 10.1016/j.jchf.2019.12.006. PubMed PMID:32241534 .
  9. Bami, K, Gandhi, S, Leong-Poi, H, Yan, AT, Ho, E, Zahrani, M et al.. Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial. J Am Soc Echocardiogr. 2020;33 (5):644-646. doi: 10.1016/j.echo.2020.02.005. PubMed PMID:32199780 .
  10. Singh, S, Adam, M, Matkar, PN, Bugyei-Twum, A, Desjardins, JF, Chen, HH et al.. Endothelial-specific Loss of IFT88 Promotes Endothelial-to-Mesenchymal Transition and Exacerbates Bleomycin-induced Pulmonary Fibrosis. Sci Rep. 2020;10 (1):4466. doi: 10.1038/s41598-020-61292-9. PubMed PMID:32161282 PubMed Central PMC7066128.
Search PubMed

Affiliations & Other Activities

  • Director, Krembil Stem Cell Facility, St. Michael’s Hospital
  • Staff Cardiologist, Division of Cardiology, St. Michael’s Hospital
  • Member, Richard Lewar Center, University of Toronto
  • Cardiologist, Division of Cardiology, Sunnybrook Health Sciences Centre